An innovative approach to treating bone tumors - starving cancer cells of the energy they need to grow - could one day provide an alternative to a commonly used chemotherapy drug without the risk of severe side effects, suggests a new study from Washington University School of Medicine in St. Louis.
2021-01-27 18:36:00 GMT2021-01-28 02:36:00(Beijing Time) Xinhua English
CHICAGO, Jan. 27 (Xinhua) A study of Washington University School of Medicine in St. Louis suggests that an innovative approach to treating bone tumors, starving cancer cells of the energy they need to grow, may one day provide an alternative to a commonly used chemotherapy drug without the risk of severe side effects.
The researchers studied an investigational drug called NCT-503, a member of a relatively new class of drugs called PHGDH inhibitors that have gained interest as potential metabolic therapies for cancer. This investigational drug prevents cancer cells from manufacturing the amino acid serine, a source of energy that fuels cancer growth.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Itamar Medical Appoints Scott P. Serota to its Board of Directors
Itamar Medical Ltd.January 27, 2021 GMT
CAESAREA, Israel, Jan. 27, 2021 (GLOBE NEWSWIRE) Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the appointment of Scott P. Serota to its Board of Directors.
Mr. Serota’s vast experience includes two decades serving as president and CEO of the Blue Cross Blue Shield Association (BCBSA), the largest health insurance provider in the U.S., covering 107 million members, or one in three of all Americans. Prior to being named president and CEO in 2000, he served four years as a senior executive including two years as chief operating officer and earlier as vice president for system development responsible for new business strateg
Washington University School of Medicine
Jennifer Lodge, PhD, the vice chancellor for research at Washington University in St. Louis, has been named the inaugural David T. Blasingame Professor.
Jennifer K. Lodge, PhD, the vice chancellor for research at Washington University in St. Louis and a leading expert in fungus that can cause a potentially fatal brain infection, has been named the inaugural David T. Blasingame Professor. She also serves as the senior associate dean for research and a professor of molecular microbiology at the School of Medicine.
The new professorship, funded by Washington University, was created to honor the extraordinary contributions of David T. Blasingame, who led the university’s Alumni & Development Office for 28 years until his retirement in 2018.
E-Mail
IMAGE: mmune cells (yellow and purple) fill a sinus (teal) in the outer layer of the meninges, the tissue that surrounds the brain and spinal cord. Researchers at Washington University School. view more
Credit: Justin Rustenhoven
Alzheimer s disease, multiple sclerosis, autism, schizophrenia and many other neurological and psychiatric conditions have been linked to inflammation in the brain. There s growing evidence that immune cells and molecules play a key role in normal brain development and function as well. But at the core of the burgeoning field of neuroimmunology lies a mystery: How does the immune system even know what s happening in the brain? Generations of students have been taught that the brain is immunoprivileged, meaning the immune system largely steers clear of it.